8-K: Stoke Therapeutics Announces Phase 3 Trial for Dravet Syndrome Treatment After Regulatory Alignment

Stoke Therapeutics has aligned with global regulatory agencies to initiate a Phase 3 study of zorevunersen, a potential disease-modifying medicine for Dravet syndrome.

Summary

• Stoke Therapeutics has finalized plans for a Phase 3 study of zorevunersen, called EMPEROR, after aligning with the FDA, EMA, and PMDA.
• The study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg of zorevunersen over 52 weeks, compared to a sham treatment, in children and adolescents aged 2 to under 18 with Dravet syndrome.
• The primary endpoint of the study is the reduction in major motor seizure frequency.
• Key secondary endpoints include improvements in cognition and behavior, measured primarily by the Vineland-3 scale.
• The company plans to initiate the Phase 3 study by mid-2025, with data anticipated by the end of 2027, pending enrollment and study timelines.
• Stoke is evaluating the commercial opportunity for zorevunersen, estimating a potential market of over 38,000 patients with Dravet syndrome across seven major markets.

Sentiment

Score: 8

Explanation: The document is very positive due to the regulatory alignment, promising clinical data, and the potential for zorevunersen to be a disease-modifying therapy. The Breakthrough Therapy Designation from the FDA also adds to the positive sentiment.

Positives

• Zorevunersen has shown substantial and durable reductions in seizure frequency in previous studies.
• The treatment has also demonstrated improvements in cognition and behavior.
• Zorevunersen has been generally well-tolerated across multiple studies, with over 600 doses administered.
• The FDA has granted zorevunersen Breakthrough Therapy Designation, which may expedite its development and review.
• The company has achieved global regulatory alignment for the Phase 3 study design.
• The study will be conducted in multiple countries, including the US, UK, EU, and Japan.
• There is a significant unmet need for disease-modifying treatments for Dravet syndrome, which zorevunersen aims to address.

Negatives

• The Phase 3 study is not expected to have data until the end of 2027, which is a long time away.
• There is a risk that positive results from earlier trials may not be replicated in the Phase 3 study.
• The company is still in the process of evaluating the commercial opportunity for zorevunersen.

Risks

• The company's ability to advance, obtain regulatory approval, and commercialize zorevunersen is subject to risks and uncertainties.
• The timing of data readouts and regulatory decisions is uncertain.
• Positive results in clinical trials may not be replicated in subsequent trials.
• The company's ability to fund development activities and achieve development goals is subject to risks.
• Global business, political, and macroeconomic conditions could impact the company's results.
• There are risks related to intellectual property protection.

Future Outlook

The company plans to initiate the Phase 3 study by mid-2025 and anticipates data by the end of 2027, pending enrollment and study timelines. They are also evaluating the commercial opportunity for zorevunersen.

Management Comments

• Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics, stated that the alignment around a global Phase 3 study design puts them one step closer to delivering the first disease-modifying medicine for Dravet syndrome.
• Dr. Kelly Knupp, M.D., MSCS, emphasized the need for medicines that address neurodevelopmental issues associated with Dravet syndrome, beyond just reducing seizures.

Industry Context

This announcement is significant as it represents a major step forward in the development of a disease-modifying therapy for Dravet syndrome, a severe and difficult-to-treat condition. Current treatments primarily focus on managing seizures, while zorevunersen aims to address the underlying genetic cause of the disease.

Comparison to Industry Standards

• Current treatments for Dravet syndrome primarily focus on reducing seizure frequency using anti-seizure medications (ASMs), but these do not address the underlying cause of the disease or the associated cognitive and behavioral issues.
• The Phase 3 study of zorevunersen is unique as it is the first study to assess the effects of a potential disease-modifying medicine on seizures as well as multiple aspects of cognition and behavior.
• Other companies are developing treatments for Dravet syndrome, but Stoke's approach of using RNA medicine to restore protein expression is novel.
• The 87% median reduction in convulsive seizure frequency observed in previous studies with zorevunersen is a significant improvement compared to the results typically seen with standard anti-seizure medications.

Stakeholder Impact

• Shareholders may see a positive impact due to the progress of zorevunersen and its potential market.
• Patients with Dravet syndrome and their families may benefit from a potential disease-modifying therapy.
• Clinicians may have a new treatment option for Dravet syndrome.
• Employees of Stoke Therapeutics may be impacted by the progress of the clinical trial.

Next Steps

• Initiate the Phase 3 EMPEROR study by mid-2025.
• Enroll approximately 150 patients in the Phase 3 study.
• Continue to work with regulatory agencies.
• Analyze data from the Phase 3 study, expected by the end of 2027.
• Evaluate the commercial opportunity for zorevunersen.

Key Dates

Keywords

Dravet syndrome, zorevunersen, Phase 3 study, seizure reduction, cognition, behavior, FDA, EMA, PMDA, disease-modifying therapy, RNA medicine, clinical trial